Savara News

Piper Sandler Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $16

Piper Sandler analyst Yasmeen Rahimi maintains $Savara(SVRA.US)$ with a buy rating, and maintains the target price at $16.According to TipRanks data, the analyst has a success rate of 35.1% and a tota

moomoo NewsJun 10 07:32 ET · Ratings

Savara to Present at the Jefferies Global Healthcare Conference

Savara Inc. (NASDAQ:SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Jefferies Global Healthcare

BusinesswireMay 29 08:05 ET

Express News | Savara Inc. : Oppenheimer Raises Target Price to $11 From $9.5

ReutersMay 21 08:10 ET

Savara Is Maintained at Outperform by Oppenheimer

Savara Is Maintained at Outperform by Oppenheimer

Dow JonesMay 21 08:10 ET

Express News | Oppenheimer Maintains Outperform on Savara, Raises Price Target to $11

BenzingaMay 21 07:59 ET

Analysts Are Bullish on These Healthcare Stocks: Savara (SVRA), Allogene Therapeutics (ALLO)

TipRanksMay 21 07:50 ET

Reported Sunday, Savara And Trillium Health Presented New Data On Autoimmune Pulmonary Alveolar Proteinosis At ATS 2024

Below are summaries of the posters presented:Poster Board 701: "Healthcare Burden of Pulmonary Alveolar Proteinosis" presented by E. Lee, M.D., Ph.D.; sponsored by Savara Inc.Presented data from a ret

BenzingaMay 20 01:46 ET

Savara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the American Thoracic Society (ATS) International Conference 2024

Savara's Partner, Trillium Health LLC, Presented Data on the Laboratory Blood Test for Diagnosing aPAP Savara Inc. (NASDAQ:SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory

BusinesswireMay 19 12:15 ET

Savara Announces New Employment Inducement Grant

Savara Inc. (NASDAQ:SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee. On May 14, 2024, the Compensation Committee

BusinesswireMay 16 16:05 ET

Savara Is Maintained at Outperform by Evercore ISI Group

Savara Is Maintained at Outperform by Evercore ISI Group

Dow JonesMay 16 13:11 ET

Express News | Evercore ISI Group Maintains Outperform on Savara, Lowers Price Target to $7

BenzingaMay 16 13:01 ET

Express News | Savara Inc : Evercore ISI Cuts Target Price to $7 From $10

ReutersMay 16 00:56 ET

Analysts Offer Insights on Healthcare Companies: Quantum-Si (QSI), Savara (SVRA) and Ventyx Biosciences (VTYX)

TipRanksMay 13 07:00 ET

Express News | HC Wainwright & Co. Reiterates Buy on Savara, Maintains $6 Price Target

BenzingaMay 13 06:41 ET

Oppenheimer Sticks to Their Buy Rating for Savara (SVRA)

TipRanksMay 10 07:58 ET

Express News | Savara Inc: With $143M in Cash and Short-Term Investments, Company Continues to Believe It Is Sufficiently Capitalized Into 2026

ReutersMay 9 17:12 ET

Savara | 10-Q: Quarterly report

SEC announcementMay 9 17:08 ET · Announcements

Express News | Savara Q1 2024 Adj EPS $(0.11) Misses $(0.10) Estimate

BenzingaMay 9 17:01 ET

Express News | Savara Inc Files for Mixed Shelf of up to $400 Mln - SEC Filing

ReutersMay 9 16:47 ET

Express News | Savara Reports First Quarter 2024 Financial Results and Provides Business Update

ReutersMay 9 16:05 ET